Description: Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. We believe that this strategy combines many of the cost efficiencies and risk abatements derived from using existing generic drugs with potential patent protections for our proprietary formulations; this strategy allows us to expedite, protect, and monetize our product candidates. Additionally, we maintain a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists, believing that this focus can potentially help reduce the cost, time and risk associated with obtaining marketing approval.
Home Page: www.lipella.com
LIPO Technical Analysis
7800 Susquehanna St.
Pittsburgh,
PA
15208
United States
Phone:
412-901-0315
Officers
| Name | Title |
|---|---|
| Dr. Jonathan Kaufman M.B.A., Ph.D. | Co-Founder, Chairman, CEO, President, Secretary & Treasurer |
| Dr. Michael B. Chancellor M.D. | Co-Founder, Chief Medical Officer & Director |
| Mr. Douglas Johnston CPA | Chief Financial Officer |
| Ms. Michele Gruber | Director of Operations |
| Katie Johnston | Controller |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1379 |
| Price-to-Sales TTM: | 7.1982 |
| IPO Date: | 2022-12-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |